Is Aquestive Therapeutics ( AQST ) Stock Outpacing Its Medical Peers This Year?
Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Arbutus ( ABUS ) Q2 Revenue Surges 529%
Arbutus Biopharma ( NASDAQ:ABUS ) , a biotechnology firm focused on treatments for chronic hepatitis B and RNA-based medicines, delivered GAAP results for Q2 2025 that greatly outpaced analyst expectations. The August 6, 2025 release showed GAAP revenue of $10.7 million, far above the $1.59 ...
Arbutus Biopharma ( ABUS ) Beats Q2 Earnings and Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to ...
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus - Arbutus Biopharma ( NASDAQ:ABUS )
Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China ...
Arbutus Biopharma ( ABUS ) Reports Q1 Loss, Tops Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -44.44% and 10.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B ( cHBV ) to date, including 2 patients who received no interferon ...
Fate Therapeutics ( FATE ) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 17.95% and 222.57%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Is Editas Medicine ( EDIT ) Stock Outpacing Its Medical Peers This Year?
Here is how Editas Medicine (EDIT) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver ( EASL ) Congress 2025
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B ( cHBV ) patients when combined with VTP-300 and low dose ...
Is Boston Scientific ( BSX ) Stock Outpacing Its Medical Peers This Year?
Here is how Boston Scientific (BSX) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Will Arbutus Biopharma ( ABUS ) Report Negative Q1 Earnings? What You Should Know
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
Five abstracts accepted for poster presentations ...
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - Arbutus Biopharma ( NASDAQ:ABUS )
WARMINSTER, Pa., April 23, 2025 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS ( "Arbutus" or the "Company" ) , a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation ...
All You Need to Know About Arbutus ( ABUS ) Rating Upgrade to Buy
Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Arbutus Biopharma ( ABUS ) Outperforming Other Medical Stocks This Year?
Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Arbutus Biopharma ( ABUS ) Reports Q4 Loss, Tops Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 12.50% and 17.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024. outcome pending ...
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 ( GLOBE NEWSWIRE ) -- Barinthus Biotherapeutics plc ( NASDAQ: BRNS ) ( "Barinthus Bio," or the "Company" ) , an immunology and inflammation ( I&I ) company focused on developing therapies that promote immune tolerance with curative ...
EyePoint Pharmaceuticals ( EYPT ) Reports Q4 Loss, Lags Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -56.10% and 21.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions ( EBS ) Q4 Earnings Top Estimates
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 114.29% and 22.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 ( GLOBE NEWSWIRE ) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle ( LNP ) patent portfolio ( a subsidiary of Roivant Sciences, Ltd. ( ...
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Arbutus Biopharma ( NASDAQ:ABUS ) , Roivant Sciences ( NASDAQ:ROIV )
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 ( GLOBE NEWSWIRE ) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle ( LNP ) patent portfolio ( a subsidiary of Roivant Sciences, Ltd.
Tarsus Pharmaceuticals, Inc. ( TARS ) Reports Q4 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 11.76% and 12.33%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - Arbutus Biopharma ( NASDAQ:ABUS )
WARMINSTER, Pa., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS ( "Arbutus" or the "Company" ) , a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., ...
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
In the dark days of the coronavirus pandemic, Moderna ( NASDAQ: MRNA ) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to market, not only protecting hundreds of millions of people from COVID-19, but also producing ...
Kymera Therapeutics ( KYMR ) Moves 7.8% Higher: Will This Strength Last?
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arbutus Provides 2025 Corporate and Financial Update
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon ...
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
WARMINSTER, Pa., Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) , ( "Arbutus" or the "Company" ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( ...
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday - Walmart ( NYSE:WMT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Macquarie boosted the price target for Trip.com Group Limited TCOM from $75.4 to $80.8.
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial ...
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B - Arbutus Biopharma ( NASDAQ:ABUS ) , Barinthus Biotherapeutics ( NASDAQ:BRNS )
Significantly greater mean declines in HBsAg levels ( p <0.017 ) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Significantly greater mean declines in HBsAg levels ( p <0.017 ) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously ...
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with ...
Karolinska Development's portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO
STOCKHOLM, Sweden, 15 November 2024. Karolinska Development AB ( Nasdaq Stockholm: KDEV ) today announces that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from today, Friday November 15th, as Dr Richard Bethell has ...
Arbutus to Present at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 14, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) , ( "Arbutus" or the "Company" ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( ...
Arbutus Biopharma ( ABUS ) Reports Q3 Loss, Lags Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 22.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Arbutus Biopharma ( NASDAQ:ABUS )
Cash runway into the fourth quarter of 2026 Conference Call and Webcast Today at 8:45 AM ET
Syndax Pharmaceuticals ( SNDX ) Reports Q3 Loss, Tops Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 23, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) , ( "Arbutus" or the "Company" ) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( ...
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Arbutus Biopharma ( NASDAQ:ABUS )
WARMINSTER, Pa., Oct. 23, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS, ( "Arbutus" or the "Company" ) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( cHBV ) ...
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024 - Arbutus Biopharma ( NASDAQ:ABUS )
WARMINSTER, Pa., Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS, ( "Arbutus" or the "Company" ) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( cHBV ) ...
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , Moderna ( NASDAQ:MRNA )
Alnylam Pharmaceuticals, Inc. ALNY and Moderna, Inc. MRNA have reached a stipulation in their ongoing patent infringement litigation. In 2022, Alnylam filed a patent infringement lawsuit against Moderna, claiming it violated a newly obtained patent.
Has Arbutus Biopharma ( ABUS ) Outpaced Other Medical Stocks This Year?
Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.
Are Medical Stocks Lagging HCA Healthcare ( HCA ) This Year?
Here is how HCA Healthcare (HCA) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) ( "Arbutus" or the "Company" ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus ( ...
Is Arbutus Biopharma ( ABUS ) Stock Outpacing Its Medical Peers This Year?
Here is how Arbutus Biopharma (ABUS) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Is Arbutus Biopharma ( ABUS ) Outperforming Other Medical Stocks This Year?
Here is how Arbutus Biopharma (ABUS) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Arbutus Biopharma ( ABUS ) Reports Q2 Loss, Tops Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -10% and 12.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
